Rapport Therapeutics, Inc.
RAPP
$14.77
-$0.16-1.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.55% | 19.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.81% | 15.25% | |||
| Operating Income | -8.81% | -15.25% | |||
| Income Before Tax | -11.09% | -20.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.09% | -20.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.09% | -20.44% | |||
| EBIT | -8.81% | -15.25% | |||
| EBITDA | -8.86% | -15.49% | |||
| EPS Basic | -10.54% | -19.76% | |||
| Normalized Basic EPS | -10.55% | -19.74% | |||
| EPS Diluted | -10.54% | -19.76% | |||
| Normalized Diluted EPS | -10.55% | -19.74% | |||
| Average Basic Shares Outstanding | 0.50% | 0.56% | |||
| Average Diluted Shares Outstanding | 0.50% | 0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||